Published in Thrombosis and Haemostasis
Published in Thrombosis and Haemostasis
Published in Thrombosis and Haemostasis
Published in Thrombosis and Haemostasis
Published in Thrombosis and haemostasis
Vorapaxar has been shown to reduce cardiovascular mortality in post-myocardial infarction (MI) patients. Pharmacodynamic biomarker research related to protease-activated receptor-1 (PAR-1) inhibition with vorapaxar in humans has short follow-up (FU) duration and is mainly focused on platelets rather than endothelial cells. This article assesses sys...
Published in Thrombosis and haemostasis
The ability to recognize and monitor atherosclerotic lesion development using noninvasive imaging is crucial in preventive cardiology. The aim of the present study was to establish a protocol for longitudinal monitoring of plaque lipid, collagen, and macrophage burden as well as of endothelial permeability. Photoacoustic signals derived from endoge...
Published in Thrombosis and Haemostasis
Published in Thrombosis and haemostasis
Although a growing number of very elderly patients with atrial fibrillation (AF), multiple conditions, and polypharmacy receive direct oral anticoagulants (DOACs), few studies specifically investigated both apixaban/rivaroxaban pharmacokinetics and pharmacodynamics in such patients. To investigate: (1) DOAC concentration-time profiles; (2) thrombin...
Published in Thrombosis and haemostasis
The relative efficacy and safety of ticagrelor and prasugrel based dual antiplatelet therapy strategies according to the platelet count (PC) in patients with acute coronary syndromes (ACS) have not been defined. This is a posthoc analysis of the ISAR-REACT 5 trial, in which patients presenting with ACS were randomized to treatment with ticagrelor v...
Published in Thrombosis and Haemostasis
